CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly.

Autor: Shue F; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA., White LJ; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA., Hendrix R; Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA., Ulrich J; Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA., Henson RL; Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA., Knight W; Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA., Martens YA; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA., Wang N; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA., Roy B; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA., Starling SC; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA., Ren Y; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA., Xiong C; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO 93110, USA., Asmann YW; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA., Syrjanen JA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester MN 55905, USA., Vassilaki M; Department of Quantitative Health Sciences, Mayo Clinic, Rochester MN 55905, USA., Mielke MM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester MN 55905, USA., Timsina J; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 93110, USA., Sung YJ; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 93110, USA., Cruchaga C; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 93110, USA., Holtzman DM; Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA., Bu G; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA., Petersen RC; Departments of Neurology, Mayo Clinic, Rochester, MN 55905, USA., Heckman MG; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, USA., Kanekiyo T; Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Jazyk: angličtina
Zdroj: Science advances [Sci Adv] 2024 Apr 05; Vol. 10 (14), pp. eadk3674. Date of Electronic Publication: 2024 Apr 03.
DOI: 10.1126/sciadv.adk3674
Abstrakt: The immune system substantially influences age-related cognitive decline and Alzheimer's disease (AD) progression, affected by genetic and environmental factors. In a Mayo Clinic Study of Aging cohort, we examined how risk factors like APOE genotype, age, and sex affect inflammatory molecules and AD biomarkers in cerebrospinal fluid (CSF). Among cognitively unimpaired individuals over 65 ( N = 298), we measured 365 CSF inflammatory molecules, finding age, sex, and diabetes status predominantly influencing their levels. We observed age-related correlations with AD biomarkers such as total tau, phosphorylated tau-181, neurofilament light chain (NfL), and YKL40. APOE4 was associated with lower Aβ42 and higher SNAP25 in CSF. We explored baseline variables predicting cognitive decline risk, finding age, CSF Aβ42, NfL, and REG4 to be independently correlated. Subjects with older age, lower Aβ42, higher NfL, and higher REG4 at baseline had increased cognitive impairment risk during follow-up. This suggests that assessing CSF inflammatory molecules and AD biomarkers could predict cognitive impairment risk in the elderly.
Databáze: MEDLINE